Severe acute respiratory syndrome coronavirus 2 structural proteins (SARS-CoV-2 structural proteins)

The structural proteins of SARS-CoV-2—specifically the Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N) proteins—are the essential building blocks of the virus and serve as the primary antigenic components for virus-like particle (VLP) vaccines (PubMed: 33053431). VLPs are self-assembling, non-infectious nanostructures that mimic the native virus's morphology without containing the viral genome, providing a safe and highly immunogenic platform for vaccination (PubMed: 34103533). The Spike protein is the most critical target as it mediates viral entry into host cells by binding to the ACE2 receptor, making it the primary focus for neutralizing antibodies (UniProt: P0DTC2). The E and M proteins are vital for viral assembly and budding, while the N protein stabilizes the viral structure and can enhance the breadth of the T-cell response (PubMed: 32835152). VLP-based vaccines, such as the plant-derived CoVifenz, utilize these components to induce robust humoral and cellular immune responses (Nature: s41591-022-01798-x). By presenting these antigens in a multivalent display, VLPs effectively prime the immune system to recognize and neutralize the SARS-CoV-2 virus upon exposure. This approach is particularly valuable for developing vaccines that are stable and potentially more resistant to variants than single-antigen platforms.

Other names

SARS-CoV-2 VLP antigensSpike, Envelope, Membrane, and Nucleocapsid proteinsSARS-CoV-2 structural proteinsS, E, M, N proteinsCoronavirus structural proteins

Induction of neutralizing antibodies and cellular immunity by presenting viral structural antigens (S, E, M, N) in a non-infectious, virus-mimicking particle format (PubMed: 34103533).